Patients newly diagnosed with breast cancer face a series of complex decisions regarding locoreginal and systemic treatment. Currently many of these decisions do not meet the definition of a high quality decision, defined as one that is both informed (based on an accurate understanding of the treatment risks and benefits) and preference-concordant (consistent with the patient's underlying preferences). I Can Decide evaluates the impact of an innovative decision tool on locoregional and systemic therapy decision making for newly diagnosed breast cancer patients.
Aim 1: Evaluate the impact of an online decision tool on the quality of decision-making for locoregional treatment among newly diagnosed patients with early stage invasive breast cancer.
Aim 2: Evaluate the impact of the decision tool on the quality of decision-making for systemic therapy among newly diagnosed patients with early stage invasive breast cancer.
Participants are 444 newly diagnosed patients with invasive early stage breast cancer, seen by 28-30 surgeons in two SEER catchment areas.